Conatus Pharma Reports Second Quarter 2017 Financial Results And Program Updates

Published: Aug 03, 2017

SAN DIEGO, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the quarter and six months ended June 30, 2017, and provided updates on its clinical development programs.

Financial Results

The net loss for the second quarter of 2017 was $5.4 million compared with $6.5 million for the second quarter of 2016.

Back to news